Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Takayuki Yoshino, Jun Watanabe, Kohei Shitara, Hirofumi Yasui, Hisatsugu Ohori, Manabu Shiozawa, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Kei Muro
Institutions: National Cancer Center Hospital East, Yokohama City University Medical Center, Shizuoka Cancer Center, Japanese Red Cross Ishinomaki Hospital, Kanagawa Cancer Center, Kyushu University, Kitasato University, Hokkaido University Hospital, Osaka National Hospital, Takeda (Japan), Yokohama City University, Saitama Cancer Center, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, National Hospital Organization, National Disaster Medical Center, National Cancer Centre Japan, Aichi Cancer Center, Aichi Cancer Center Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286437555